The genus *Elizabethkingia* comprises aerobic, non-fermenting, non-motile and non-spore-forming gram-negative rods that were previously named *Flavobacterium* or belonged to CDC group IIa and later reclassified as *Chryseobacterium* in 1994[@b1]. In 2005, *Chryseobacterium meningosepticum* and *C. miricola* were transferred to a new genus, *Elizabethkingia*, on the basis of combined phenotypic and phylogenetic characteristics[@b2]. The genus comprises three medically important species, *Elizabethkingia anophelis*, *E. meningoseptica* and *E. miricola*. A novel species, *E. endophytica*, isolated from sweet corn, was also recently proposed[@b3]. *E. meningoseptica,* previously named *Flavobacterium meningosepticum* or *C. meningosepticum*, is the best known species among the genus. *E. meningoseptica* is a causative agent of nosocomial infections especially in immunocompromised patients, as well as neonatal meningitis and sepsis[@b4]. Besides soil, fresh water and plants, the bacterium can be found in hospital environments and may contaminate flushing solutions and medical devices[@b5]. Infections caused by *E. meningoseptica* can be difficult to treat and carry high mortalities, which may be partly explained by their intrinsic multidrug resistance towards commonly used antibiotics such as β-lactams and aminoglycosides[@b6]. Therefore, accurate diagnosis is important to guide appropriate antibiotic regimens which often consist of a combination of ciprofloxacin or rifampicin with piperacillin-tazobactam or vancomycin.

In contrast to *E. meningoseptica*, the epidemiology and pathogenicity of *E. anophelis* and *E. miricola* were less well understood. *E. miricola*, originally named *C. miricola* when first isolated from condensed water obtained from the Russian space station, Mir, only rarely causes nosocomial infections in human[@b7][@b8]. On the other hand, *E. anophelis* was first isolated from midgut of the mosquito *Anopheles gambiae* in 2011[@b9]. Soon after its discovery, it was reported to cause neonatal meningitis in the Central African Republic and a nosocomial outbreak in an intensive-care unit in Singapore[@b10][@b11]. The first discovery of *E*. *anophelis* from mosquito gut has raised suspicion on mosquitoes as the source of neonatal meningitis cases in Africa[@b10]. However, our recent report on *E. anophelis* meningitis in two neonates and chorioamnionitis in a neonate's mother in Hong Kong suggested that mosquitoes were unlikely the vehicles of transmission[@b12]. Since the transmission route was initially obscure, draft genome sequencing was performed and showed evidence for perinatal vertical transmission from a mother to her neonate[@b12]. The ultimate resolution power of genome sequencing also enabled species confirmation and discrimination from the phenotypically similar species, *E. meningoseptica*[@b12].

Since *E. anophelis* was commonly misidentified as *E. meningoseptica* in previous reports[@b10][@b11][@b12][@b13], we hypothesize that many previously described *E. meningoseptica* isolates were actually *E. anophelis* and that *E. anophelis* may account for a significant proportion of *Elizabethkingia* infections. To better understand the epidemiology and clinical disease spectrum of *E. anophelis* and *Elizabethkingia* as a whole, we determined the clinical and molecular epidemiology of bacteremia caused by *Elizabethkingia-*like species from five regional hospitals in Hong Kong. All bacteremia episodes caused by *Elizabethkingia-*like species identified by conventional phenotypic tests from 2004 to 2013 during the study period were included. For the 45 episodes of *Elizabethkingia*-like bacteremia identified, 16S rRNA gene sequencing was performed for species identification and clinical characteristics and outcomes were analyzed.

Results
=======

Identification of *Elizabethkingia*-like bacteremia by 16S rRNA gene sequencing
-------------------------------------------------------------------------------

Twenty-one of the 45 episodes of *Elizabethkingia*-like bacteremia were caused by *Elizabethkingia*, while 24 episodes were caused by diverse genera/species including *Chryseobacterium* (n = 15), *Flavobacterium* (n = 1), *Planobacterium* (n = 6), *Sphingobacterium* (n = 1) and *Weeksella*-like species (n = 1) according to 16S rRNA gene analysis ([Fig. 1](#f1){ref-type="fig"} and see [Supplementary Table 1](#S1){ref-type="supplementary-material"}). Of the 21 episodes of *Elizabethkingia* bacteremia, 17 were caused by *E. anophelis* (99.0--99.9% nucleotide identity to *E. anophelis* type strain R26^T^), three by *E. meningoseptica* (99.4--99.8% nucleotide identity to *E. meningoseptica* type strain ATCC 13253^T^) and one by *E. miricola* (99.5% nucleotide identity to *E. miricola* type strain LMG 22470^T^).

Among the 24 episodes of non-*Elizabethkingia* bacteremia, 15 were caused by *Chryseobacterium* species, among which two (C13 and C15) represented two potentially novel *Chryseobacterium* species (≤98.4% nucleotide identity to existing *Chryseobacterium* species). One episode was caused by another potentially novel species most closely related to *Weeksella* (91.9% nucleotide identity to *Weeksella virosa* DSM 16922^T^). The other eight episodes were caused by *Planobacterium* (n = 6), *Flavobacterium* (n = 1) and *Sphingobacterium* (n = 1) species respectively.

Clinical characteristics of patients with *Elizabethkingia*-like bacteremia
---------------------------------------------------------------------------

The clinical characteristics of the 45 episodes of *Elizabethkingia*-like bacteremia were summarized in [Tables 1](#t1){ref-type="table"}, [2](#t2){ref-type="table"}, [3](#t3){ref-type="table"}. Of the 17 episodes of *E. anophelis* bacteremia, the male:female ratio was 11:6, with a median age of 58 years (range, 1 day to 104 years) ([Table 2](#t2){ref-type="table"}). Most patients had underlying diseases. Except two patients with pseudobacteremia, most cases were associated with clinically significant bacteremia, with 12 cases being hospital-acquired and three community-acquired. The most common diagnosis was pneumonia (n = 5), followed by catheter-related bacteremia (n = 4), neonatal meningitis (n = 3), nosocomial bacteremia (n = 2) and neutropenic fever (n = 1). Among the five cases of pneumonia, three were community-acquired, including one in a 51-year-old previously healthy man (case EA10). All three cases of neonatal meningitis were hospital-acquired. Details of two (HKU36 and HKU38) of the three neonatal meningitis cases have been reported previously[@b12]. They were included because they fell into the inclusion criteria during the study period. The source of *E. anophelis* in the two cases of nosocomial bacteremia and one case of neutropenic fever was obscure, although severe mucositis was present in the latter. Three of the 17 patients had multiple positive blood cultures. *E. anophelis* was concomitantly isolated from other body sites in seven patients, including cerebrospinal fluid (n = 3), respiratory samples (n = 3) and catheter tip (n = 1). Most patients survived, but four patients died despite appropriate antibiotics given in two of the four patients. Complications as a result of *E. anophelis* bacteremia included acute pulmonary edema, congestive heart failure, multi-organ failure, disseminated intravascular coagulation, septic shock, haematemesis, acute renal failure, metabolic acidosis and intraventricular haemorrhage. Various antibiotic regimens as single drug or combinations were used for empirical or definitive treatment, including quinolones, penicillins, cephalosporins, carbapenems, vancomycin and rifampicin. Removal of catheter was often required in catheter-related bacteremia cases in addition to antibiotic treatment.

All the four patients with *E. meningoseptica* or *E. miricola* bacteremia also had underlying disease and clinically significant infections ([Table 2](#t2){ref-type="table"}). Two patients with *E. meningoseptica* bacteremia had biliary tract infections, while one had nosocomial bacteremia. Interestingly, the only episode of *E. miricola* bacteremia (case EMI1) was detected in the same patient with *E. anophelis* nosocomial pneumonia (case EA1) which occurred more than one month previously during the same admission and was complicated by heart failure and acute pulmonary edema requiring intubation and inotropes. Five weeks after successful treatment with piperacillin-tazobactam, the patient developed another episode of bacteremia caused by *E. miricola* which was also isolated from central venous catheter. The patient recovered with levofloxacin and catheter removal.

In contrast, 16 of the 24 patients with bacteremia due to non-*Elizabethkingia* species had pseudobacteremia ([Table 3](#t3){ref-type="table"}). The other eight patients were diagnosed to have nosocomial bacteremia (three cases), transfusion-related bacteremia (two cases), catheter-related bacteremia (one case), neutropenic fever (one case) and sepsis (one case). Except for a case of community-acquired sepsis in a 90-year-old man (case P1), all other cases were hospital-acquired. Only one episode of catheter-related bacteremia was complicated by septic shock, where *C. arthrosphaerae* was isolated from six blood cultures. All the eight patients survived.

Comparison between *Elizabethkingia* and non-*Elizabethkingia* cases showed that clinically significant infections were more common in patients with *Elizabethkingia* bacteremia than those with non-*Elizabethkingia* bacteremia (i.e. fewer pseudobacteremia cases were observed) (*P* \< 0.01). Moreover, patients with *Elizabethkingia* bacteremia had more positive cultures from other sites (*P* \< 0.05) and lower incidence of polymicrobial bacteremia (*P* \< 0.01). They also showed higher complication (*P* \< 0.05) and mortality (*P* \< 0.05) rates than those with with non-*Elizabethkingia* bacteremia ([Table 1](#t1){ref-type="table"}).

Microbiological characteristics of *Elizabethkingia* isolates
-------------------------------------------------------------

All the 21 *Elizabethkingia* isolates were non-motile, oxidase-positive, catalase-positive, indole-positive, non-glucose-fermenting, Gram-negative bacilli. Growth on MacConkey agar, citrate utilization, urea hydrolysis and fermentation of cellobiose and melibiose fermentation were variable. All 21 isolates were identified as *E. meningoseptica* by Vitek 2 GNI system with 91--99% confidence. All 21 isolates were susceptible to ciprofloxacin, cefoperazone-sulbactam and vancomycin, but were resistant or intermediate-resistant to imipenem, amikacin, gentamicin and tobramycin. Susceptibilities to ceftazidime, piperacillin, rifampicin and cotrimoxazole were variable (see [Supplementary Table 2](#S1){ref-type="supplementary-material"}).

MALDI-TOF MS using Reference Library Biotyper v3.1.2.0 (Bruker Daltonik, Germany) failed to identify the 17 *E. anophelis* isolates (10 misidentified as *E. meningoseptica* with score 2.073 to 2.403, two identified as *Elizabethkingia* species with score 1.952--1.971 and five unidentified with score 1.32 to 1.42 to *E. meningoseptica*). When the database was expanded with inclusion of mass spectra from seven *E*. *anophelis* isolates, all the other 10 *E. anophelis* isolates were correctly identified as *E. anophelis* with score 2.321 to 2.634. The three *E. meningoseptica* and one *E. miricola* strains were correctly identified by the Bruker reference library (see [Supplementary Table 2](#S1){ref-type="supplementary-material"}). Hierarchical cluster analysis showed that the protein mass spectra of *E. anophelis* and *E. miricola* were clustered together but formed a distinct branch from *E. meningoseptica* ([Fig. 2](#f2){ref-type="fig"}).

PFGE typing of *E. anophelis*
-----------------------------

To determine the genetic relatedness of the 17 *E. anophelis* strains isolated from five different hospitals, PFGE was performed using the bacterial genomic and DNA restriction endonuclease *Xba*I. In general, the PFGE patterns among the 17 *E. anophelis* strains were distinct from each other and different from that of the type strain R26^T^. Dendrogram constructed using the PFGE images showed that some adjacently clustered strains were isolated from the same hospital ([Fig. 3](#f3){ref-type="fig"}). For example, strains EA2, EA3 and EA4 were from hospital 5, while strains EA13 and EA15 were from hospital 6. However, no clear epidemiological linkage could be identified in terms of time and place of blood culture isolation. Specifically, strains EA2, EA3 and EA4 were isolated from different years. Strains EA13 and EA15 were isolated four months apart and the two patients were hospitalized in different wards of hospital 6.

Discussion
==========

*E. anophelis* bacteremia should be considered clinically significant unless proven otherwise and should prompt appropriate antibiotic therapy. In contrast to the traditional belief that *E. meningoseptica* was the most important *Elizabethkingia* species associated with bacteremia, the present study showed that the majority of *Elizabethkingia* bacteremia cases were caused by *E. anophelis*. In particular, neonatal meningitis was associated exclusively with *E. anophelis* in this study. In the present series, *E. anophelis* bacteremia mainly occurred in neonates or adults with underlying medical illnesses, and was most commonly associated with pneumonia and hospital-acquired infections such as catheter-related bacteremia and neonatal meningitis. Notably, community-acquired pneumonia occurred in three patients including a healthy middle-aged adult, where the infective source remained obscure. Apart from the two previous reported cases of neonatal meningitis (HKU36 and HKU38) which were most likely acquired from maternal-to-infant transmission based on comparative genomics[@b12], no obvious epidemiological linkage or genetic relatedness was identified among the other cases. Nevertheless, some potentially genetically related strains upon PFGE analysis may have circulated in the same hospital. Further studies should be performed to better understand the disease spectrum and transmission routes of *E. anophelis*.

*E. anophelis* bacteremia carries significant morbidity and mortality. Various complications were observed and four patients died, giving a mortality rate of 23.5%. This is in line with previous reports of *E. anophelis* neonatal meningitis being associated with poor outcomes[@b10]. Nevertheless, all the three present cases of neonatal meningitis were cured with early use of appropriate antibiotics[@b12]. Although *E. anophelis* usually confers resistance to multiple antibiotics such as ceftazidime, imipenem and aminoglycosides[@b12], all the 17 isolates were susceptible to ciprofloxacin, cefoperazone-sulbactam and vancomycin, which should be considered in empirical treatment while awaiting susceptibility results. In cases of catheter-related bacteremia, infected catheters should be removed in addition to antibiotic treatment. Future prospective studies with population-based data should be performed to determine the prevalence or incidence of *E. anophelis* bacteremia.

*E. meningoseptica* and *E. miricola* appeared to be much less prevalent than *E. anophelis*, although similar studies in other countries are required to more accurately assess their relative importance. Similar to *E. anophelis*, *E. meningoseptica* and *E. miricola* bacteremia were associated with clinically significant infections. Besides one case of *E. meningoseptica* nosocomial bacteremia and one case of *E. miricola* catheter-related bacteremia, biliary tract infections were also noted in two cases of *E. meningoseptica* bacteremia. It remains to be determined if *E. meningoseptica* may have the propensity to cause biliary tract infections among the genus. Given their similar antibiotic susceptibility profiles to that of *E. anophelis*, ciprofloxacin, cefoperazone-sulbactam and vancomycin should also be included in treatment regimens for *E. meningoseptica* and *E. miricola* bacteremia.

In contrast to *Elizabethkingia* species, isolation of non-*Elizabethkingia* species from blood cultures should raise suspicion of their clinical significance. In this study, non-*Elizabethkingia* bacteremia is associated with higher incidence of pseudobacteremia and polymicrobial bacteremia than *Elizabethkiniga* bacteremia. In particular, all six isolates of *C. indologenes* and the three potentially novel species were associated with pseudobacteremia. Bacteremia caused by non-*Elizabethkingia* species is also associated with lower incidence of complications and mortality than *Elizabethkingia* bacteremia, suggesting that these bacterial species may be less virulent than *Elizabethkingia*. Moreover, these environmental, non-*Elizabethkingia* bacterial species may contaminate blood cultures when aseptic techniques during blood taking are breached. Careful clinical assessment is required to determine the clinical significance and the need for antibiotics when these bacteria are isolated from blood cultures.

Although the two *E. anophelis* strains, HKU36 and EA14, are phylogenetically genetically close to *E. endophytica* strain JM-87^T^, they should belong to *E. anophelis* instead of *E. endophytica* or a novel species. The two strains possessed 99.9% nucleotide identities to both the newly proposed species, *E. endophytica* strain JM-87^T^ and *E. anophelis* R26^T^ in their 16S rRNA gene sequences. Although strain JM-87^T^ was reported to possess 51--52% similarities to *E. anophelis* R26^T^ by DNA-DNA hybridization[@b3], our previous study showed that the draft genome of strain HKU36 possessed 78.3% nucleotide identity to the genome of *E. anophelis* R26^T^ by estimation of intergenomic distance[@b12]. Given the close relatedness of strains HKU36, EA14 and JM-87^T^ in their 16S rRNA genes ([Fig. 1](#f1){ref-type="fig"}), it is likely that the genome sequences of strain JM-87^T^ and EA14 may also possess \>70% identity to that of *E. anophelis* R26^T^. Since genome-based comparison can offer ultimate resolution for species delineation which is superior to traditional DNA-DNA hybridization methods, genome sequencing of strain JM-87^T^ and related strains such as EA14 should be performed to more accurately define their taxonomic positions.

The present results confirmed our suspicion that *E. anophelis* was a previously under-reported bacterium which can be easily misidentified as *E. meningoseptica*[@b12]. Although *E*. *anophelis* was first discovered from mosquito gut[@b10], we previously showed that maternal chorioamnionitis, instead of mosquitoes, was more likely the source of neonatal meningitis[@b12]. Similarly, mosquitoes are unlikely the route of transmission in other *E. anophelis* infections. We speculate that contaminated environments, such as infected catheters, are the source of infection in most cases, as in the case of previously described "*E. meningoseptica*" infections. Given their similar phenotypic characteristics, *E. anophelis* isolates from previous reports were often mistaken as *E. meningoseptica* initially[@b10][@b11][@b12][@b14]. Phenotypic tests, such as acid production from cellobiose and citrate utilization, previously reported as potentially useful for species discrimination[@b12], were unlikely to be reliable. In our previous study, the three *E. anophelis* strains were also initially misidentified as *E. meningoseptica* even with MALDI-TOF MS, owing to the absence of *E. anophelis* spectra in commercial databases[@b12]. The 16S rRNA genes of *E. anophelis* possessed \>98% nucleotide identity to those of *E. meningoseptica* and *E. miricola*, which should offer sufficient discriminative power[@b12]. However, some "*E. meningoseptica"* strains with 16S rRNA sequences deposited in GenBank, such as strains G3-1-08 and 502[@b15][@b16], should belong to *E. anophelis* based on phylogenetic analysis[@b12]. These "misidentified" strains in GenBank may confuse the interpretation of 16S rRNA gene sequencing results and should be rectified[@b12]. While *E. anophelis* can be distinguished from *E. meningoseptica* by MALDI-TOF MS when the database is expanded with mass spectra from *E. anophelis* strains, *E. anophelis* and *E. miricola* appear to be indistinguishable from each other. With an expanded database using *E. anophelis* isolates, MALDI-TOF MS is the method of choice for rapid and accurate diagnosis of *E. anophelis* infections, which is crucial to better understand its epidemiology and clinical disease spectrum.

Methods
=======

Ethics statement
----------------

The use of blood culture isolates and anonymous clinical data were approved by Institute Review Board, The University of Hong Kong/Hospital Authority, Hong Kong (reference UW 04-278 T/600). The methods and all experimental protocols were carried out in accordance with the approved guidelines. Since this study does not involve experimentation on human subjects or the use of tissue samples from human subjects, written informed consent has been waived by our institutional review board.

Settings and Patients
---------------------

Patients were hospitalized in five regional hospitals located in different areas of Hong Kong from 2004 to 2013. To identify potential cases of *Elizabethkingia* bacteremia, all bacteremia episodes caused by oxidase-positive, non-glucose fermenters that were identified as *Elizabethkingia*, *Flavobacterium* or *Chryseobacterium* species by conventional phenotypic tests during the study period were included with clinical data analyzed[@b17]. Bacteremia was categorized as clinically significant or pseudobacteremia (contamination of blood culture) by clinical and laboratory criteria[@b18]. The criteria include the patient's clinical presentation, physical examination findings, body temperature at the time of the blood culture, leukocyte and differential cell counts, imaging or operative results, histopathological findings, number of positive blood cultures out of the total number performed, and response to treatment.

Bacterial isolates
------------------

Collection of clinical specimens, bacterial cultures and conventional phenotypic identification were performed according to standard protocols[@b19]. Two of the 45 *Elizabethkingia*-like isolates from two neonates (HKU36 and HKU38) have been reported previously[@b12]. The same isolate recovered from the same patient was counted only once.

16S rRNA gene sequencing for species identification
---------------------------------------------------

The 45 blood culture isolates were subject to 16S rRNA gene sequencing according to previously published protocols with modifications, using primers LPW57 (5′-AGTTTGATCCTGGCTCAG-3′) and LPW58 (5′-AGGCCCGGGAACGTATTCAC-3′)[@b12][@b20]. The sequences of PCR products were compared to known gene sequences in GenBank by multiple sequence alignment using CLUSTAL_W in MEGA version 6[@b21]. Phylogenetic tree was constructed by maximum likelihood method using MEGA version 6[@b21].

Statistical analysis
--------------------

A comparison of characteristics was made between patients with *Elizabethkingia* and non-*Elizabethkingia* bacteremia using Chi-square test (IBM SPSS Statistics version 19). *P* \< 0.05 was regarded as statistically significant.

Phenotypic characterization and matrix-assisted laser-desorption ionization-time-of-flight mass-spectrometry (MALDI-TOF MS) of *Elizabethkingia* isolates
---------------------------------------------------------------------------------------------------------------------------------------------------------

The 21 *Elizabethkinigia* isolates were characterized by phenotypic tests, Vitek 2 GNI system (bioMérieux, France) and MALDI-TOF MS. MALDI-TOF MS was performed by ethanol formic acid extraction method as described previously, using Bruker Daltonics microflex LT system with Reference Library Biotyper v3.1.2.0 (Bruker Daltonik, Germany)[@b22][@b23]. Since *E. anophelis* is not included in the Bruker reference, mass spectra generated from seven *E. anophelis* strains with identity confirmed by 16S rRNA gene sequencing were later added to the database. Obtained spectra were subject to hierarchical cluster analysis as described previously[@b24]. Antibiotic susceptibility testing was performed by Kirby Bauer disk diffusion method with results interpreted according to Clinical and Laboratory Standards Institute for *Staphylococcus aureus* (vancomycin) and *Pseudomonas aeruginosa* (other drugs), because of the lack of interpretative criteria for *Elizabethkingia*[@b25].

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

The 17 *E. anophelis* isolates were characterized by PFGE using CHEF Mapper XA system (Bio-Rad, CA, USA) and restriction endonuclease *Xba*I as described previously[@b12][@b26]. After PFGE, the gel was stained with ethidium bromide (1 μg/ml) for 30 minutes and the patterns of the genomic DNA digest were visualized with a UV transilluminator. Digital images were stored electronically as TIFF files and analyzed visually and with GelCompar II (version 3.0; Applied Maths, Kortrijk, Belgium), and represented by UPGMA method.

Nucleotide sequence accession number
------------------------------------

The 16S rRNA gene sequences of the 45 blood culture isolates have been deposited in the GenBank sequence database under accession no. KP875383 to KP875427.
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![Phylogenetic tree showing the relationship of the 45 *Elizabethkingia*-like blood culture isolates to related bacterial species using 16S rRNA gene sequence analysis.\
The tree was constructed by maximum likelihood method using General Time Reversible model and *Escherichia coli* (CP010304) as the root. A total of 1325 nucleotide positions were included in the analysis. Bootstrap values were calculated from 1000 replicates. The scale bar indicates the number of substitutions per site. Names and accession numbers are given as cited in GenBank database.](srep26045-f1){#f1}

![Results of MALDI-TOF MS identification of the 21 *Elizabethkingia* strains.\
In panel (**A**), representative MALDI-TOF MS spectra of the three *Elizabethkingia* species are shown. In panel (**B**), dendrogram was generated from hierarchical clustering of MALDI-TOF MS spectra of 21 *Elizabethkingia* isolates and reference strains of *E. meningoseptica* and *E. miricola*, using ClinProTools 3.0 (Bruker Daltonics, Germany). Distances are displayed in relative units.](srep26045-f2){#f2}

![Pulsed-field gel electrophoresis (PFGE) analysis of the 17 *E. anophelis* isolates and *E. anophelis* type strain R26^T^.\
(lane 1 = EA1, lane 2 = EA2, lane 3 = EA3, lane 4 = EA4, lane 5 = EA5, lane 6 = EA6, lane 7 = EA7, lane 8 = EA8, lane 9 = EA9, lane 10 = EA10, lane 11 = EA11, lane 12 = EA12, lane 13 = EA13, lane 14 = EA14, lane 15 = EA15, lane 16 = HKU38, lane 17 = HKU36, lane 18 = R26^T^, M = lambda marker). In Panel (**A**), PFGE was performed using CHEF Mapper XA system (Bio-Rad) and restriction endonuclease *Xba*I. Results showed that the 17 isolates possessed distinct PFGE patterns. In Panel (**B**), dendrogram was constructed with PFGE data by similarity and clustering analysis using the Dice coefficient (1% tolerance and 0.5% optimization) and unweighted pair-group method using average linkages with GelCompar II.](srep26045-f3){#f3}

###### Characteristics of the 45 patients with bacteremia caused *Elizabethkingia-*like organisms

  Characteristics                       Number of patients (%)   *P*-value^c^  
  ------------------------------------ ------------------------ -------------- ---------
  Sex (male:female)                             11:10               13:11        0.90
  Underlying diseases                         19 (90.5)            24 (100)      0.12
  Hospital- vs community-acquired^a^             15:4                7:1         0.60
  Diagnosis^b^                                                                 
   Biliary tract infection                     2 (9.5)              0 (0)        0.12
   Catheter-related bacteremia                 5 (23.8)            1 (4.2)       0.05
   Community-acquired pneumonia                3 (14.3)             0 (0)        0.06
   Neonatal meningitis                         3 (14.3)             0 (0)        0.06
   Neutropenic fever                           1 (4.8)             2 (8.3)       0.63
   Nosocomial bacteremia                       3 (14.3)            5 (20.8)      0.57
   Nosocomial pneumonia                        2 (9.5)              0 (0)        0.12
   Primary bacteremia                           0 (0)              1 (4.2)       0.34
   Pseudobacteremia                            2 (9.5)            16 (76.1)     0.00009
  \>1 positive blood cultures                  3 (14.3)            1 (4.2)       0.23
  Polymicrobial bacteremia                      0 (0)             10 (41.7)     0.0008
  Positive cultures from other sites           8 (38.1)            1 (4.2)       0.005
  Complications                                7 (33.3)            1 (4.2)       0.01
  Attributable mortality                       4 (19.0)             0 (0)        0.025

^a^excluding pseudobacteremia.

^b^The percentages add up to more than 100% because some patients have more than one diagnosis.

^c^by Chi-square test.

###### Clinical characteristics of patients with *Elizabethkingia* bacteremia.

  Case/strain no.        Sex   Age  Underlying diseases                                                        Diagnosis                                            Community- or hospital-acquired   No. of positive blood cultures (concomitant isolates)   Other culture-positive specimens  Antibiotic treatment                                          Complications/outcomee
  --------------------- ----- ----- -------------------------------------------------------------------------- --------------------------------------------------- --------------------------------- ------------------------------------------------------- ---------------------------------- ------------------------------------------------------------- --------------------------------------
  *E. anophelis*                                                                                                                                                                                                                                                                                                                                              
  EA1                     M    54   DM, hyperlipidemia, ischemic cardiomyopathy                                Nosocomial pneumonia                                               HA                                            1                                           None                Piperacillin-tazobactam                                       Acute pulmonary edema, CHF, survived
  EA2                     M    65   HT, DM, CAD, PVD, RAS, hyperlipidemia, carotid stenosis                    Pseudobacteremia                                                   NA                                            1                                           None                Cloxaciillin and levofloxacin, then amoxicillin-clavulanate   Survived
  EA3                     F    1m   Prematurity, twin, RDS, PDA                                                Catheter-related bacteremia                                        HA                                            3                                           None                Vancomycin, cefoperazone-sulbactam                            Multi-organ failure, died
  EA4                     F    8d   Imperforated anus, rectovaginal fistula                                    Neonatal meningitis                                                HA                                            2                                           CSF                 Vancomycin and rifampicin                                     Survived
  EA5                     M    65   COPD, CAD, CHF, AF, CRHD, right hip AVN                                    Community-acquired pneumonia                                       CA                                            1                                          Sputum               Ciprofloxacin                                                 Survived
  EA6                     M    37   Dilated cardiomyopathy, CAD                                                Nosocomial bacteremia                                              HA                                            1                                           None                Ciprofloxacin                                                 DIC, survived
  EA7                     F    64   HT, hyperlipidemia, stage 4 DLBC lymphoma                                  Neutropenic fever, severe mucositis                                HA                                            2                                           None                Meropenem                                                     Septic shock, haematemesis, died
  EA8                     M    68   HT, CRF, AAA                                                               Nosocomial bacteremia                                              HA                                            1                                    Tracheal aspirate          Levofloxacin and vancomycin                                   Acute renal failure, died
  EA9                     M    73   CA hypopharynx, CA ampulla of Vater                                        Pseudobacteremia                                                   NA                                            1                                           None                Cefuroxime                                                    Survived
  EA10                    M    51   None                                                                       Community-acquired pneumonia                                       CA                                            1                                          Sputum               Ampicillin-sulbactam, then ciprofloxacin                      Survived
  EA11                    F    104  HT, CAD, CVA, nephrotic syndrome                                           Community-acquired pneumonia                                       CA                                            1                                           None                Amoxicillin-clavulanate                                       Died
  EA12                    M    59   obesity, DM, CAD                                                           Catheter-related bacteremia, drip site cellulitis                  HA                                            1                                           None                Levofloxacin                                                  Survived
  EA13                    F    35   Epilepsy, HT, ESRF on HD                                                   Catheter-related bacteremia                                        HA                                            1                                           None                Levofloxacin                                                  Survived
  EA14                    M    58   CRHD with AVR, ESRF on HD                                                  Catheter-related bacteremia                                        HA                                            1                                       Catheter tip            Piperacillin-tazobactam, then levofloxacin                    Septic shock, survived
  EA15                    M    88   COPD, old PTB                                                              Nosocomial (aspiration) pneumonia                                  HA                                            1                                           None                Levofloxacin                                                  Survived
  HKU36                   M    21d  None                                                                       Neonatal meningitis                                                HA                                            1                                           CSF                 Vancomycin, piperacillin and rifampicin                       Survived
  HKU38                   F    1d   Apnea of prematurity                                                       Neonatal meningitis                                                HA                                            1                                           CSF                 Vancomycin, piperacillin-tazobactam and rifampicin            metabolic acidosis, IVH, survived
  *E. meningoseptica*                                                                                                                                                                                                                                                                                                                                         
  EME1                    M    51   Asthma, HT, scoliosis, MSSA infective spondylitis                          Nosocomial bacteremia                                              HA                                            1                                           None                Ticarcillin-clavulanate                                       Survived
  EME2                    M    52   Biliary pancreatitis, RPC, cholecystectomy, cirrhosis with biliary stent   Post-cholangiogram acute cholangitis                               HA                                            1                                           None                Levofloxacin and metronidazole                                Survived
  EME3                    F    89   HT, AF, painless obstructive jaundice on palliative stenting               Biliary sepsis                                                     CA                                            1                                           None                Levofloxacin                                                  Survived
  *E. miricola*                                                                                                                                                                                                                                                                                                                                               
  EMI1                    M    54   DM, hyperlipidemia, ischemic cardiomyopathy                                Catheter-related bacteremia                                        HA                                            1                                       CVP catheter            Levofloxacin                                                  Survived

^a^AAA, abdominal aortic aneurysm; AF, atrial fibrillation; AVN, avascular necrosis; AVR, atrial valve replacement; CA, carcinoma; CA, community-acquired; CAD, coronary artery disease; CHF, congestive heart failure; COPD; chronic obstructive pulmonary disease; CRF, chronic renal failure; CRHD, chronic rheumatic heart disease; CSF, cerebrospinal fluid; CVA, cerebrovascular accident; CVP, central venous pressure; DIC, disseminated intravascular coagulation; DLBC, diffuse large B cell; DM, diabetes mellitus; ESRF, end-stage renal failure; HA, hospital-acquired; HD, hemodialysis; HT, hypertension; IVH, intraventricular hemorrhage; MSSA, methicillin-sensitive *Staphylococcus aureus*; NA, not applicable; PDA, patent ductus arteriosus; PTB, pulmonary tuberculosis; PVD, peripheral vascular disease; RAS, renal artery stenosis; RDS, respiratory distress syndrome; RPC, recurrent pyogenic cholangitis.

###### Clinical characteristics of patients with non-*Elizabethkingia* bacteremia.

  Case/ strain no.                                 Sex   Age  Underlying diseases                                                Diagnosis                                         Community- or hospital-acquired                 No. of positive blood cultures (concomitant isolates)                  Other culture-positive specimens  Treatment + removal of catheter              Complications + outcome
  ----------------------------------------------- ----- ----- ------------------------------------------------------------------ ------------------------------------------------ --------------------------------- ------------------------------------------------------------------------------------ ---------------------------------- -------------------------------------------- -------------------------
  Potentially novel *Chryseobacterium* species                                                                                                                                                                                                                                                                                                                                           
  C13                                               M    64   Metastatic pancreatic carcinoma, sepsis                            Postmortem pseudobacteremia                                     NA                                                          1                                                          None                NA                                           Died (non-attributable)
  C15                                               M    68   Head injury                                                        Pseudobacteremia                                                NA                                    1 (*Acinetobacter sp., Enterococcus faecium*)                                     No                 Amoxicillin-clavulanate                      Survived
  *Chryseobacterium arthrosphaerae*                                                                                                                                                                                                                                                                                                                                                      
  C1                                                M    82   HT, gout, BPH, bilateral hydronephrosis and hydroureter            Nosocomial bacteremia                                           HA                                                          1                                                          None                Piperacillin-tazobactam, then levofloxacin   Survived
  C2                                                F    48   Stage IV DLBC lymphoma                                             Catheter-related bacteremia, neutropenic fever                  HA                                 6 (*Klebsiella pneumoniae, Acinetobacter baumanii*)                           Central catheter          Imipenem-cilastatin and amikacin             Septic shock, survived
  C9                                                M    56   COPD, pneumothorax                                                 Nosocomial bacteremia                                           HA                                                          1                                                          None                Ticarcillin-clavulanate, levofloxacin        Survived
  *Chryseobacterium gallinarum*                                                                                                                                                                                                                                                                                                                                                          
  C14                                               M     1   Cow milk allergy                                                   Nosocomial bacteremia                                           HA                                                          1                                                          None                Piperacillin-tazobactam                      Survived
  *Chryseobacterium hominis*                                                                                                                                                                                                                                                                                                                                                             
  C8                                                F    76   DM, HT, CVA, CHF, AAA, PVD, hyperlipidemia                         Pseudobacteremia                                                NA                                                          1                                                          None                None                                         Survived
  C12                                               F    51   AML                                                                Neutropenic fever                                               HA                                                 1 (*Moraxella sp.*)                                                 None                Piperacillin-tazobactam, vancomycin          Survived
  *Chryseobacterium indologenes*                                                                                                                                                                                                                                                                                                                                                         
  C3                                                F    58   Hyperlipidemia, IgA nephropathy, Multiple myeloma                  Pseudobacteremia                                                NA                           1 (*Stenotrophomonas maltophila, Commamonas sp,, Ralstonia sp.*)                          None                Levofloxacin, piperacillin-tazobactam        Survived
  C4                                                F    49   DM, CRF, bilateral hydronephrosis, perinephric and psoas abscess   Pseudobacteremia                                                NA                            1 (*Enterococcus facaelis, A. baumanii, Streptococcus mitis*)                            None                Cefuroxime, ampicillin, levofloxacin         Survived
  C5                                                M    78   HT, gout, CA caecum with metastases, thyroidectomy                 Pseudobacteremia                                                NA                                                  1 (*A. baumanii*)                                                  None                Amoxicillin-clavulanate, ciprofloxacin       Survived
  C6                                                F    57   CA rectum, mania, small bowel obstruction                          Pseudobacteremia                                                NA                                           1 (*E. facaelis*, *A. baumanii*)                                          None                Amoxicillin-clavulanate                      Survived
  C7                                                M    84   HT, AF,CRHD, CVA, gout, BPH COPD                                   Pseudobacteremia                                                NA                                                          1                                                          None                Amoxicillin-clavulanate                      Survived
  C10                                               F    56   Acute encephalopathy, aspiration pneumonia, sepsis                 Postmortem pseudobacteremia                                     NA                  1 (*Pseuodmonas putida*, *Bacillus* sp., CNS, MSSA, non-hemolytic *Streptococcus*)                 None                NA                                           Died (non-attributible)
  *Chryseobacterium taihuense*                                                                                                                                                                                                                                                                                                                                                           
  C11                                               M    85   DM, DU, BPH                                                        Pseudobacteremia                                                NA                                                          1                                                          None                Amoxicillin-clavulanate                      Survived
  *Flavobacterium lindanitolerans*                                                                                                                                                                                                                                                                                                                                                       
  F1                                                F    30   SLE, lupus nephritis                                               Nosocomial (post-transfusion) bacteremia                        HA                                                  1(*Bacillus sp.*)                                                  None                Levofloxacin                                 Survived
  *Planobacterium taklimakanense*                                                                                                                                                                                                                                                                                                                                                        
  P1                                                M    90   CAD, COPD, DM, BPH                                                 Primary bacteremia                                              CA                                                          1                                                          None                Ceftriaxone                                  Survived
  P2                                                M    1d   RDS, congenital pneumonia                                          Pseudobacteremia                                                NA                                                          1                                                          None                Penicillin and netilmicin                    Survived
  P3                                                F    99   COPD, CVA, intertrochanteric fracture                              Pseudobacteremia                                                NA                                                          1                                                          None                Amoxicillin-clavulanate                      Survived
  P4                                                M    56   COPD, BPH, PTB                                                     Pseudobacteremia                                                NA                                                          1                                                          None                Levofloxacin                                 Survived
  P5                                                M    52   NPC, thyroidectomy, hypothyroidism                                 Nosocomial (post-transfusion) bacteremia                        HA                                                          1                                                          None                Piperacillin-tazobactam                      Survived
  P6                                                F    1m   Sepsis, hypoglycemia                                               Pseudobacteremia                                                NA                                                          1                                                          None                Cefotaxime                                   Survived
  *Sphingobacterium daejeonense*                                                                                                                                                                                                                                                                                                                                                         
  S1                                                M    94   COPD, cor pulmonale, BPH, gout, Shy-Drager syndrome, CAD           Pseudobacteremia                                                NA                                                 1 (*K. pneumoniae*)                                                 None                Cotrimoxazole                                Survived
  Potentially novel *Weeksella*-related species                                                                                                                                                                                                                                                                                                                                          
  W1                                                F    18d  RSV pneumonia                                                      Pseudobacteremia                                                NA                                                          1                                                          None                Ampicillin, netilmicin and erythromycin      Survived

^a^AAA, abdominal aortic aneurysm; AF, atrial fibrillation; AML, acute myeloid leukemia; BPH, benign prostatic hyperplasia; CA, carcinoma; CA, community-acquired; CAD, coronary artery disease; CHF, congestive heart failure; CNS, coagulase-negative *Staphylococcus*; COPD; chronic obstructive pulmonary disease; CRF, chronic renal failure; CRHD, chronic rheumatic heart disease; CVA, cerebrovascular accident; DLBC, diffuse large B cell; DM, diabetes mellitus; DU, Duodenal ulcer; HA, hospital-acquired; HT, hypertension; MSSA, methicillin-sensitive *Staphylococcus aureus*; NA, not applicable; NPC, nasopharyngeal carcinoma; PTB, pulmonary tuberculosis; PVD, peripheral vascular disease; RDS, respiratory distress syndrome; RSV, respiratory syncytial virus; SLE, systemic lupus erythematosus.
